Gustavsson B G, Brandberg A, Regårdh C G, Almersjö O E
J Pharmacokinet Biopharm. 1979 Dec;7(6):665-73. doi: 10.1007/BF01061213.
The serum and urinary concentrations of 5-FU after continuous portal and jugular infusion have been followed by means of a highly sensitive microbiological assay method. Our data indicate that more than 90% of 5-FU was eliminated in the liver after continuous portal infusion of 0.625 mg x kg-1 x hr-1, corresponding to a dose of 15 mg x kg-1 x 24 hr-1. Negligible amounts of intact 5-FU were excreted into the bile, and the urinary excretion was only a few percent of the amount infused. The arterial concentration was on average tenfold higher during the continuous jugular infusion than after the continuous portal infusion, indicating that the route of administration has a pronounced effect on the disposition of 5-FU. Twenty-three percent of the jugular dose reached the liver; 77% was degraded by extrahepatic metabolism. Of these, degradation in the prehepatic splanchnic area accounted for 15%.
采用高灵敏度微生物检测方法,对持续门静脉和颈静脉输注5-氟尿嘧啶(5-FU)后的血清和尿液浓度进行了跟踪监测。我们的数据表明,以0.625mg·kg⁻¹·hr⁻¹的速率持续门静脉输注5-FU(相当于15mg·kg⁻¹·24hr⁻¹的剂量)后,超过90%的5-FU在肝脏中被清除。完整的5-FU排泄到胆汁中的量可忽略不计,尿液排泄量仅为输注量的百分之几。持续颈静脉输注期间的动脉血浓度平均比持续门静脉输注后高10倍,这表明给药途径对5-FU的处置有显著影响。颈静脉输注剂量的23%到达肝脏;77%通过肝外代谢降解。其中,肝前内脏区域的降解占15%。